Nuvo Pharmaceuticals Inc. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported revenue was CAD 15.64 million compared to CAD 14.42 million a year ago. Net income was CAD 2.03 million compared to net loss of CAD 17.99 million a year ago. Basic earnings per share from continuing operations was CAD 0.18 compared to basic loss per share from continuing operations of CAD 1.58 a year ago. Diluted loss per share from continuing operations was CAD 0.01 compared to CAD 1.58 a year ago.